Using serum DNA methylation to monitor hepatocellular carcinoma
Official title: he Application of DNA Methylation for Patients Who Had Hepatocellular Carcinoma With Normal Serum Alpha-fetoprotein
Run by Chiayi Christian Hospital · NCT05764551 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if changes in DNA found in blood can help track how well treatment is working for people with liver cancer who have normal alpha-fetoprotein levels.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Chiayi Christian Hospital Academic / other |
| Locations | 1 site (Chiayi City) |
| Trial ID | NCT05764551 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 20 and older diagnosed with hepatocellular carcinoma and normal serum alpha-fetoprotein levels.
✕Probably not a fit
Patients with non-HCC diagnoses, concurrent malignancies, or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective study aims to evaluate the role of serum DNA methylation in patients with hepatocellular carcinoma (HCC) who have normal alpha-fetoprotein levels. Participants will undergo serum DNA methylation testing before treatment and at regular intervals thereafter to assess changes that may correlate with treatment response or recurrence of HCC. The study will observe patients for up to 96 weeks, with additional testing conducted if recurrence occurs during this period. The goal is to determine the effectiveness of serum DNA methylation as a biomarker for HCC management.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive method for monitoring HCC recurrence and treatment response.
How similar studies have gone: While the application of serum DNA methylation is a novel approach in this context, similar studies have shown promise in other cancer types.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 20 years old * The diagnosis of hepatocellular carcinoma (HCC) according to AASLD 2018 clinical guidelines or histology report * Individuals with HCC and normal serum alpha-fetorpotein level (\<20 ng/ml) * Individuals who could sign informed consent Exclusion Criteria: * The histology report revealed non-HCC, HCC mixed with cholangiocarcinoma or sarcomatoid HCC * Individuals with HCC and other concurrent malignancies * Individuals with chronic kidney disease who could not tolerate contrast-enhanced dynamic images * Individuals ever receiving any organ transplantation * Individuals with HIV infection * Individuals who could not able to understand and sign informed consent
Where it's running
-
Ditmanson Medical Foundation Chiayi Christian Hospital
Chiayi City, Taiwan Recruiting
Study contacts
- Principal investigator: Po-Yueh Chen, M.D — Ditmanson Medical Foundation Chiayi Christian Hospital
- Study coordinator: Po-Yueh Chen, M.D
- Email: hdilwy7@gmail.com
- Phone: +886-5-2765041
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InstaSure Non-Invasive Finger-Press Test for HCC
This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer
This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)
This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.
-
GLP-1 RA plus standard treatment in first-line metastatic GI cancers
This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.